免疫組織化学市場：製品タイプ、疾患タイプ、エンドユーザー、用途別-2025-2030年の世界予測

免疫組織化学市場は、2023年に29億8,000万米ドルと評価され、2024年には31億5,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には44億6,000万米ドルになると予測されています。

免疫組織化学（IHC）は、解剖学的、免疫学的、生化学的手法を融合した重要な技術であり、特定の抗体を利用して細胞内の特定の抗原を同定します。IHCの必要性は、がんのような疾患の病因に関する貴重な洞察を提供する能力にあり、治療計画のカスタマイズを可能にし、診断精度を高め、治療成績を向上させる。その応用範囲は病理学、腫瘍学、医薬品開発に及び、病院、診断研究所、研究機関において重要な役割を果たしています。慢性疾患の流行拡大、技術の進歩、個別化医療に対する需要の高まりが、この市場の成長を後押ししています。しかし、高コスト、技術の複雑さ、熟練した専門家の不足といった課題が大きな障壁となっています。主な成長要因としては、正確な診断が必要となるがん患者の増加やバイオマーカー研究の急増が挙げられます。デジタル病理学や自動化プラットフォームのような技術革新は、効率と精度を高めるだけでなく、単一のプラットフォームで包括的な分析を提供するマルチプレックスアッセイの開発にもつながります。このような機会を活用するために、企業は共同研究、先端技術への投資、製品ポートフォリオの拡大に注力すべきです。しかし、規制上のハードルを乗り越え、厳格な品質管理基準を維持することは依然として課題です。コスト効率に優れ、特異性が高く、堅牢な抗体の開発に重点を置いた革新的技術や、AIを活用した画像解析や新規診断法は、有望な研究手段です。市場はダイナミックで、応用能力を拡大するための技術進歩や戦略的提携が重視されています。そのため、最先端技術への投資や研究開発の強化に取り組む企業は、成長するIHC市場を活用し、満たされていないニーズに対応し、将来の成長を促進する上で有利な立場にあります。

市場力学：急速に進化する免疫組織化学市場の主要市場インサイトを公開

免疫組織化学市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんや自己免疫疾患などの慢性疾患の人口増加
  • がん診断法を改善するための政府資金とイニシアチブの増加
  • 個別化/カスタマイズ医療に対する需要の高まり
• 市場抑制要因
  • 生検サンプルの収集、保管、使用に関する問題
• 市場機会
  • 自動化および半自動化システムのイントロダクション免疫組織化学
  • 診断企業、研究機関、ヘルスケア間の連携
• 市場の課題
  • 製品の不具合や熟練専門家の不足に関する懸念

ポーターの5つの力：免疫組織化学市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫組織化学市場における外部からの影響の把握

外部マクロ環境要因は、免疫組織化学市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析免疫組織化学市場における競合情勢の把握

免疫組織化学市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス免疫組織化学市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫組織化学市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨免疫組織化学市場における成功への道筋を描く

免疫組織化学市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口におけるがんや自己免疫疾患などの慢性疾患の蔓延
    • がん診断の改善に向けた政府の資金援助と取り組みの拡大
    • パーソナライズ/カスタマイズ医療の需要の高まり
  • 抑制要因
    • 生検サンプルの収集、保管、使用に関する問題
  • 機会
    • 自動および半自動免疫組織化学システムのイントロダクション
    • 診断会社、調査機関、ヘルスケアの連携
  • 課題
    • 製品の故障や熟練した専門家の不足に関する懸念
• 市場セグメンテーション分析
  • 応用：犯罪現場での組織サンプルや体液の識別のための法医学における免疫組織化学の使用の増加
  • 製品：正確で信頼性の高い結果を得るための二次抗体の需要増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 免疫組織化学市場：製品別

• 抗体
  • 一次抗体
  • 二次抗体
• 装置
  • スライドスキャナ
  • スライド染色システム
  • 組織マイクロアレイ
  • 組織処理システム
• キット
• 試薬
  • ブロッキング血清と試薬
  • 発色基質
  • 希釈剤
  • 固定試薬
  • 組織学的染色
  • 有機溶剤
  • タンパク質分解酵素
  • 安定剤

第7章 免疫組織化学市場：疾患タイプ別

• 自己免疫疾患
• がん
• 心血管疾患
• 糖尿病
• 感染症
• 腎臓疾患

第8章 免疫組織化学市場：エンドユーザー別

• 学術調査機関
• CRO
• 法医学研究所
• 病院および診断研究所
• 製薬・バイオ医薬品企業

第9章 免疫組織化学市場：用途別

• 診断
• 薬物検査
• 法医学

第10章 南北アメリカの免疫組織化学市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の免疫組織化学市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの免疫組織化学市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • テンパスは、精密医療と標的がん治療を強化するために、高度なHER2およびFOLR1 IHC検査を開始
  • ロシュ社、VENTANA HER2（4B5）検査のCEマークを取得、ENHERTUによるHER2低発現転移性乳がんの治療選択肢を拡大
  • 細胞シグナル伝達技術がSignalStar Multiplex IHC技術を導入
  • ダナハー社、英国拠点のアブカム社を買収し、新薬発見と疾患マッピング能力を強化
• 戦略分析と提言

企業一覧

• Agilent Technologies Inc.
• Becton, Dickinson & Company
• Bio SB
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Biocare Medical LLC
• Biogenex Laboratories
• CANDOR Bioscience GmbH
• Cell Signaling Technology, Inc.
• Danaher Corporation
• Diagnostic BioSystems Inc.
• Eagle Biosciences, Inc.
• Elabscience Biotechnology Inc.
• F. Hoffman-La Roche AG
• Genemed Biotechnologies, Inc. by Sakura Finetek Japan Co., Ltd
• Histo-Line Laboratories
• Lunaphore Technologies SA
• Merck KGaA
• Miltenyi Biotec B.V. & Co. KG
• PerkinElmer Inc.
• Rockland Immunochemicals, Inc.
• Takara Bio, Inc
• Thermofisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. IMMUNOHISTOCHEMISTRY MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOHISTOCHEMISTRY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. IMMUNOHISTOCHEMISTRY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. IMMUNOHISTOCHEMISTRY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOHISTOCHEMISTRY MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SLIDE STAINING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TISSUE MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TISSUE PROCESSING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BLOCKING SERA & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC SUBSTRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DILUENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FIXATION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HISTOLOGICAL STAINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ORGANIC SOLVENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PROTEOLYTIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEPHROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FORENSIC LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PHARMA & BIOPHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 70. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 71. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. CANADA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 107. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 108. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 109. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 114. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 115. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 116. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. INDIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 149. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 156. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 157. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 163. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 164. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 165. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 170. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 171. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 172. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 177. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 178. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 179. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. VIETNAM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 190. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 192. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 193. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 194. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. DENMARK IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 199. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 200. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 201. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. EGYPT IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 206. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 207. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 208. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 209. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 210. FINLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 213. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 214. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 215. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 216. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. FRANCE IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 220. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 221. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 222. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 223. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. GERMANY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 227. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 228. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 229. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. ISRAEL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 234. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 235. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 236. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 237. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. ITALY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 240. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 241. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 242. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 243. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 244. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 245. NETHERLANDS IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 246. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 247. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 248. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 249. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 250. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 251. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. NIGERIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 254. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 255. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 256. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 257. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 258. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 259. NORWAY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 262. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 263. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 264. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 265. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 266. POLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 267. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 268. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 269. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 270. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 271. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. QATAR IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 274. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 275. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 276. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 277. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 278. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 279. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 280. RUSSIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 282. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 283. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 284. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 285. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 286. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 287. SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 288. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 290. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 291. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 292. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 293. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 294. SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 295. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 296. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 297. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 298. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 299. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 300. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 301. SPAIN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 302. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 303. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 304. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 305. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 306. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 307. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. SWEDEN IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 309. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 310. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 311. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 312. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 313. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 314. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 315. SWITZERLAND IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 316. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 317. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 318. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 319. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 320. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 321. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 322. TURKEY IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 323. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 324. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 325. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 326. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 327. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 328. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 329. UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 330. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 331. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 332. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 333. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 334. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 335. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 336. UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 337. IMMUNOHISTOCHEMISTRY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 338. IMMUNOHISTOCHEMISTRY MARKET, FPNV POSITIONING MATRIX, 2023

The Immunohistochemistry Market was valued at USD 2.98 billion in 2023, expected to reach USD 3.15 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.46 billion by 2030.

Immunohistochemistry (IHC) is a critical technique that merges anatomical, immunological, and biochemical methods to identify specific antigens in cells by utilizing specific antibodies, thus offering a profound impact on diagnostic and pharmaceutical fields. The necessity of IHC lies in its capability to provide valuable insights into the pathogenesis of diseases like cancer, enabling the customization of treatment plans, enhancing diagnostic accuracy, and advancing therapeutic outcomes. Its application spans pathology, oncology, and drug development, serving crucial roles in hospitals, diagnostic laboratories, and research institutions. The expanding prevalence of chronic diseases, technological advancements, and an increasing demand for personalized medicine drive growth in this market. However, challenges such as high costs, the complexity of techniques, and limited availability of skilled professionals pose significant barriers. Key growth influences include an increase in cancer cases that necessitate precise diagnostics and the surge in biomarker research. Opportunities arise from technological innovations like digital pathology and automated platforms that boost efficiency and accuracy, as well as the development of multiplex assays that offer comprehensive analysis on a singular platform. To harness these opportunities, companies should focus on collaborative research, investing in advanced technologies, and expanding their product portfolios. However, navigating regulatory hurdles and maintaining rigorous quality control standards remain challenging. Innovations focusing on developing cost-effective, highly specific, and robust antibodies, along with leveraging AI for image analysis and novel diagnostic methods, represent promising research avenues. The market is dynamic, with a substantial emphasis on technological progression and strategic partnerships to broaden application capabilities. Thus, businesses that invest in cutting-edge technologies and robust R&D efforts are well-positioned to capitalize on the growing IHC market, addressing unmet needs and driving future growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunohistochemistry Market

The Immunohistochemistry Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Extensive prevalence of chronic diseases such as cancer and autoimmune diseases among population
  • Increasing government funding and initiatives to improve cancer diagnostics
  • Growing demand for personalized/customized medicine
• Market Restraints
  • Issues related to the collection, storage, and use of biopsy samples
• Market Opportunities
  • Introduction of automated and semi-automated immunohistochemistry systems
  • Collaborations between diagnostic companies, research institutes, and healthcare
• Market Challenges
  • Concerns pertinent to product failure and shortage of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Immunohistochemistry Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunohistochemistry Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunohistochemistry Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunohistochemistry Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunohistochemistry Market

A detailed market share analysis in the Immunohistochemistry Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunohistochemistry Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunohistochemistry Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunohistochemistry Market

A strategic analysis of the Immunohistochemistry Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunohistochemistry Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies Inc., Becton, Dickinson & Company, Bio SB, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Biocare Medical LLC, Biogenex Laboratories, CANDOR Bioscience GmbH, Cell Signaling Technology, Inc., Danaher Corporation, Diagnostic BioSystems Inc., Eagle Biosciences, Inc., Elabscience Biotechnology Inc., F. Hoffman-La Roche AG, Genemed Biotechnologies, Inc. by Sakura Finetek Japan Co., Ltd, Histo-Line Laboratories, Lunaphore Technologies SA, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PerkinElmer Inc., Rockland Immunochemicals, Inc., Takara Bio, Inc, and Thermofisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Immunohistochemistry Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Antibodies, Equipment, Kits, and Reagents. The Antibodies is further studied across Primary Antibodies and Secondary Antibodies. The Equipment is further studied across Slide Scanners, Slide Staining Systems, Tissue Microarrays, and Tissue Processing Systems. The Reagents is further studied across Blocking Sera & Reagents, Chromogenic Substrates, Diluents, Fixation Reagents, Histological Stains, Organic Solvents, Proteolytic Enzymes, and Stabilizers.
• Based on Disease Type, market is studied across Autoimmune Diseases, Cancer, Cardiovascular Diseases, Diabetes Mellitus, Infectious Diseases, and Nephrological Diseases.
• Based on End-user, market is studied across Academic & Research Institutes, CROs, Forensic Labs, Hospitals & Diagnostic Laboratories, and Pharma & Biopharma Companies.
• Based on Application, market is studied across Diagnostics, Drug Testing, and Forensic.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Extensive prevalence of chronic diseases such as cancer and autoimmune diseases among population
    • 5.1.1.2. Increasing government funding and initiatives to improve cancer diagnostics
    • 5.1.1.3. Growing demand for personalized/customized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to the collection, storage, and use of biopsy samples
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of automated and semi-automated immunohistochemistry systems
    • 5.1.3.2. Collaborations between diagnostic companies, research institutes, and healthcare
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns pertinent to product failure and shortage of skilled professionals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Application: Increasing usage of immunohistochemistry in forensic science for the identification of tissue samples and body fluids at crime scenes
  • 5.2.2. Product: Increasing demand for secondary antibodies for accurate and reliable results
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunohistochemistry Market, by Product

• 6.1. Introduction
• 6.2. Antibodies
  • 6.2.1. Primary Antibodies
  • 6.2.2. Secondary Antibodies
• 6.3. Equipment
  • 6.3.1. Slide Scanners
  • 6.3.2. Slide Staining Systems
  • 6.3.3. Tissue Microarrays
  • 6.3.4. Tissue Processing Systems
• 6.4. Kits
• 6.5. Reagents
  • 6.5.1. Blocking Sera & Reagents
  • 6.5.2. Chromogenic Substrates
  • 6.5.3. Diluents
  • 6.5.4. Fixation Reagents
  • 6.5.5. Histological Stains
  • 6.5.6. Organic Solvents
  • 6.5.7. Proteolytic Enzymes
  • 6.5.8. Stabilizers

7. Immunohistochemistry Market, by Disease Type

• 7.1. Introduction
• 7.2. Autoimmune Diseases
• 7.3. Cancer
• 7.4. Cardiovascular Diseases
• 7.5. Diabetes Mellitus
• 7.6. Infectious Diseases
• 7.7. Nephrological Diseases

8. Immunohistochemistry Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. CROs
• 8.4. Forensic Labs
• 8.5. Hospitals & Diagnostic Laboratories
• 8.6. Pharma & Biopharma Companies

9. Immunohistochemistry Market, by Application

• 9.1. Introduction
• 9.2. Diagnostics
• 9.3. Drug Testing
• 9.4. Forensic

10. Americas Immunohistochemistry Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Immunohistochemistry Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Immunohistochemistry Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Tempus launches advanced HER2 and FOLR1 IHC tests to enhance precision medicine and targeted cancer therapies
  • 13.3.2. Roche secures CE Mark for VENTANA HER2 (4B5) test, enhancing treatment options for HER2-low metastatic breast cancer with ENHERTU
  • 13.3.3. Cell signaling technology introduces SignalStar Multiplex IHC technology
  • 13.3.4. Danaher Corporation to acquire UK-based Abcam to enhance drug discovery and disease mapping capabilities
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies Inc.
• 2. Becton, Dickinson & Company
• 3. Bio SB
• 4. Bio-Rad Laboratories Inc.
• 5. Bio-Techne Corporation
• 6. Biocare Medical LLC
• 7. Biogenex Laboratories
• 8. CANDOR Bioscience GmbH
• 9. Cell Signaling Technology, Inc.
• 10. Danaher Corporation
• 11. Diagnostic BioSystems Inc.
• 12. Eagle Biosciences, Inc.
• 13. Elabscience Biotechnology Inc.
• 14. F. Hoffman-La Roche AG
• 15. Genemed Biotechnologies, Inc. by Sakura Finetek Japan Co., Ltd
• 16. Histo-Line Laboratories
• 17. Lunaphore Technologies SA
• 18. Merck KGaA
• 19. Miltenyi Biotec B.V. & Co. KG
• 20. PerkinElmer Inc.
• 21. Rockland Immunochemicals, Inc.
• 22. Takara Bio, Inc
• 23. Thermofisher Scientific, Inc.